+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asthma Spacers Market - Forecasts from 2022 to 2027

  • PDF Icon


  • 124 Pages
  • March 2022
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5576488
The asthma spacers market is expected to reach a market size worth US$2,389.953 million by 2027, growing at a CAGR of 4.57%. This market was valued at US$1,747.452 million in 2020.

An asthma spacer is a holding chamber attached to an asthma medicine dispensing machine, commonly known as an inhaler, facilitating slower and effective inhalation of the medicine. An asthma inhaler converts the medicine into gas form and delivers it to the patients’ lungs, opening the airways. However, the inhaler has less mouth space and rushes the medicine into the person's airways, making it hard to inhale the medicine and even leading to wastage. A spacer is attached to the inhaler, which is a long tube that enables the patients to slowly inhale the medicine reducing the wastage and enabling better inhalation. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the market growth during the forecasted period. Rising cases of asthma, especially among children, are expected to drive the market demand since children find it difficult to inhale through the inhaler directly.

Geographically, the asthma spacer market is divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific regions for the study. The Asia Pacific asthma spacer market is expected to grow at a lucrative rate during the forecasted period. Surging air pollution to hazardous levels has significantly increased the cases of asthma among all age groups, children being the worst affected. Data from UNEP shows that 70% of air pollution-linked deaths occur in the Asia Pacific region. Asthma is the prime chronic disease that prevails due to air pollution and causes death. Growing cases of asthma are expected to drive the market demand for asthma spacers in the region. North America and European regions are anticipated to dominate the market owing to higher expenditure capability and significant users.

Growth Factor

Growing cases of asthma, especially among children, have raised concerns and increased market adoption of asthma inhalers and spacers.

Asthma is a widely prevalent respiratory chronic disease that affects the airways, making it difficult for the person to breathe owing to narrowed and/ or swelled up airways. One of the prime reasons expected to drive the market growth of asthma spacers is the growing cases of asthma worldwide, especially among children. Data from the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) shows that globally, more than 3 billion people suffer from asthma. The World Health Organization database shows that 461,000 people died because of this disease in 2019. Increasing cases of asthma owing to family genetics and rising air pollution are expected to increase the adoption of asthma inhalers and spacers, driving the market growth during the forecast period.

Market Restraints

The development of spacer-free technology to reduce the overall cost of medication and home invented substitutes recommended by WHO constraints the market growth of asthma spacers.

The World Health Organization (WHO) aims to reduce global asthma under its Global Action Plan for the Prevention and Control of NCDs, 2030. A study by the organization observed that only 1/5th of patients suffering from asthma have access to inhalers, and the majority were not aware of the usage and importance of spacers. In its guidelines and awareness programs, WHO promoted the making and usage of homemade spacers using plastic bottles, which could be substituted for branded asthma spacers. The low cost of the homemade spacers accompanied by high treatment and medication costs encourages the adoption of DIY spacers, especially in low-income countries, and hence constraints the prospective opportunity for the market.

Furthermore, the development of technology and the launch of new products that do not require a spacer for inhalation pose a significant market threat for asthma spacers. Teva Pharmaceuticals. for instance, has successfully formulated spacer-free asthma medication, which enables better breathing for the patients. QVAR® RediHaler™ is an FDA-approved spacer-free technology that delivers medication as effectively as its predecessor. QVAR® RediHaler™ has been developed around breath-actuated inhaler technology and is apt for four years and older patients, which can be used without the spacer, even for children. The rise in such technology is expected to hinder the market for the asthma spacer industry. 

COVID-19 Insights

With the outbreak of the virus, governments around the world implemented a nationwide lockdown which confined the population within the four walls of their homes. The COVID-19 virus is a respiratory system affecting virus which makes breathing hard for the affected person. Furthermore, the virus was observed to cause a more severe impact on patients already suffering from chronic diseases, especially asthma and other respiratory diseases. With the outbreak of the virus and growing cases, people adopted inhalers and spacers for greater medicine delivery, supporting the market.

Key Market Segments

By Product Type

  • AeroChamber
  • OpticChamber
  • Easivent
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others
Frequently Asked Questions about the Global Asthma Spacers Market

What is the estimated value of the Global Asthma Spacers Market?

The Global Asthma Spacers Market was estimated to be valued at $1747.45 million in 2020.

What is the growth rate of the Global Asthma Spacers Market?

The growth rate of the Global Asthma Spacers Market is 4.5%, with an estimated value of $2389.95 million by 2027.

What is the forecasted size of the Global Asthma Spacers Market?

The Global Asthma Spacers Market is estimated to be worth $2389.95 million by 2027.

Who are the key companies in the Global Asthma Spacers Market?

Key companies in the Global Asthma Spacers Market include Zydus Cadila, Pari Gmbh, Cipla, Glaxo SmithKline Pharmaceuticals Ltd, Rossmax International Ltd. and Lupin.

Table of Contents

1. INTRODUCTION1.1. Market Definition
1.2. Market Segmentation

2.2. Assumptions

3. EXECUTIVE SUMMARY3.1. Research Highlights

4. MARKET DYNAMICS4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.2. AeroChamber
5.3. OpticChamber
5.4. Easivent
5.5. Others 

6.2. Online
6.3. Offline 

7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom 
7.4.4. Spain 
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. South Korea
7.6.4. Taiwan
7.6.5. Thailand
7.6.6. Indonesia 
7.6.7. Japan
7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES9.1. Zydus Cadila
9.2. Pari Gmbh
9.3. Cipla
9.4. Glaxo SmithKline Pharmaceuticals Ltd
9.5. Rossmax International Ltd.
9.6. Lupin

Companies Mentioned

  • Zydus Cadila
  • Pari Gmbh
  • Cipla
  • Glaxo SmithKline Pharmaceuticals Ltd
  • Rossmax International Ltd.
  • Lupin